INTRODUCTION: HIV drug resistance (HIVDR) testing is not routinely available in many resource-limited settings, therefore, antiretroviral therapy (ART) program and site factors known to be associated with HIVDR should be monitored to optimize the quality of patient care and minimize the emergence of preventable HIVDR. METHODS: In 2009, Namibia selected 5 World Health Organization Early Warning Indicators (EWIs) and piloted abstraction at 9 ART sites: "ART prescribing practices, patients lost to follow-up at 12 months, patient retention on first-line ART at 12 months, on-time antiretroviral drug pick-up, and antiretroviral drug-supply continuity". RESULTS: Records supported monitoring of 3 of 5 selected EWIs. Nine of 9 (100%) sites met the target of 100% initiated on appropriate first-line regimens. Eight of 9 (89%) sites met the target of ≤20% lost to follow-up, although 20.8% of ART starters (range: 4.6%-44.6%) had a period of absence without documented ART coverage of 2.3 months (range: 1.5-3.9 months). Six of 9 (67%) sites met the target of 0% switched to a second-line regimen. CONCLUSIONS: EWI monitoring directly resulted in public health action which will optimize the quality of care, specifically the strengthening of ART record systems permitting monitoring of 5 EWIs in future years and protocols for improved ART patient defaulter tracing.
INTRODUCTION: HIV drug resistance (HIVDR) testing is not routinely available in many resource-limited settings, therefore, antiretroviral therapy (ART) program and site factors known to be associated with HIVDR should be monitored to optimize the quality of patient care and minimize the emergence of preventable HIVDR. METHODS: In 2009, Namibia selected 5 World Health Organization Early Warning Indicators (EWIs) and piloted abstraction at 9 ART sites: "ART prescribing practices, patients lost to follow-up at 12 months, patient retention on first-line ART at 12 months, on-time antiretroviral drug pick-up, and antiretroviral drug-supply continuity". RESULTS: Records supported monitoring of 3 of 5 selected EWIs. Nine of 9 (100%) sites met the target of 100% initiated on appropriate first-line regimens. Eight of 9 (89%) sites met the target of ≤20% lost to follow-up, although 20.8% of ART starters (range: 4.6%-44.6%) had a period of absence without documented ART coverage of 2.3 months (range: 1.5-3.9 months). Six of 9 (67%) sites met the target of 0% switched to a second-line regimen. CONCLUSIONS: EWI monitoring directly resulted in public health action which will optimize the quality of care, specifically the strengthening of ART record systems permitting monitoring of 5 EWIs in future years and protocols for improved ARTpatient defaulter tracing.
Authors: D Descamps; P Flandre; V Calvez; G Peytavin; V Meiffredy; G Collin; C Delaugerre; S Robert-Delmas; B Bazin; J P Aboulker; G Pialoux; F Raffi; F Brun-Vézinet Journal: JAMA Date: 2000-01-12 Impact factor: 56.272
Authors: Joep J van Oosterhout; Neena Bodasing; Johnstone J Kumwenda; Cooper Nyirenda; Jane Mallewa; Paul R Cleary; Michel P de Baar; Rob Schuurman; David M Burger; Eduard E Zijlstra Journal: Trop Med Int Health Date: 2005-05 Impact factor: 2.622
Authors: A Molla; M Korneyeva; Q Gao; S Vasavanonda; P J Schipper; H M Mo; M Markowitz; T Chernyavskiy; P Niu; N Lyons; A Hsu; G R Granneman; D D Ho; C A Boucher; J M Leonard; D W Norbeck; D J Kempf Journal: Nat Med Date: 1996-07 Impact factor: 53.440
Authors: Jean B Nachega; Michael Hislop; David W Dowdy; Richard E Chaisson; Leon Regensberg; Gary Maartens Journal: Ann Intern Med Date: 2007-04-17 Impact factor: 25.391
Authors: D R Kuritzkes; J B Quinn; S L Benoit; D L Shugarts; A Griffin; M Bakhtiari; D Poticha; J J Eron; M A Fallon; M Rubin Journal: AIDS Date: 1996-08 Impact factor: 4.177
Authors: Robert S Hogg; David R Bangsberg; Viviane D Lima; Chris Alexander; Simon Bonner; Benita Yip; Evan Wood; Winnie W Y Dong; Julio S G Montaner; P Richard Harrigan Journal: PLoS Med Date: 2006-09 Impact factor: 11.069
Authors: M R Jordan; D E Bennett; M A Wainberg; D Havlir; S Hammer; C Yang; L Morris; M Peeters; A M Wensing; N Parkin; J B Nachega; A Phillips; A De Luca; E Geng; A Calmy; E Raizes; P Sandstrom; C P Archibald; J Perriëns; C M McClure; S Y Hong; J H McMahon; N Dedes; D Sutherland; S Bertagnolio Journal: Clin Infect Dis Date: 2012-05 Impact factor: 9.079
Authors: Steven Y Hong; Jean B Nachega; Karen Kelley; Silvia Bertagnolio; Vincent C Marconi; Michael R Jordan Journal: Infect Disord Drug Targets Date: 2011-04
Authors: Vincent C Marconi; Baohua Wu; Jane Hampton; Claudia E Ordóñez; Brent A Johnson; Dinesh Singh; Sally John; Michelle Gordon; Anna Hare; Richard Murphy; Jean Nachega; Daniel R Kuritzkes; Carlos del Rio; Henry Sunpath Journal: AIDS Patient Care STDS Date: 2013-12 Impact factor: 5.078
Authors: Steven Y Hong; Anna Jonas; Michael DeKlerk; Andreas Shiningavamwe; Tiruneh Desta; Alfons Badi; Lynn Morris; Gillian M Hunt; Johanna Ledwaba; Heidi B Sheehan; Kiger Lau; Andrew Trotter; Alice M Tang; Christine Wanke; Michael R Jordan Journal: J Acquir Immune Defic Syndr Date: 2015-04-01 Impact factor: 3.731
Authors: James H McMahon; Julian H Elliott; Steven Y Hong; Silvia Bertagnolio; Michael R Jordan Journal: PLoS One Date: 2013-02-12 Impact factor: 3.240
Authors: Serge C Billong; Joseph Fokam; Armand S Nkwescheu; Etienne Kembou; Pascal Milenge; Zephirin Tsomo; Grace Ngute Dion; Avelin F Aghokeng; Eitel N Mpoudi; Peter M Ndumbe; Vittorio Colizzi; Jean B Elat Nfetam Journal: PLoS One Date: 2012-05-17 Impact factor: 3.240
Authors: Anna Jonas; Justice Gweshe; Milner Siboleka; Michael Deklerk; Michael Gawanab; Alfons Badi; Victor Sumbi; Dawn Pereko; Abraham Blom; Samson Mwinga; Michael R Jordan; Logan Jerger; Kiger Lau; Steven Y Hong Journal: PLoS One Date: 2013-06-07 Impact factor: 3.240
Authors: Joseph Fokam; Serge C Billong; Anne C Z K Bissek; Etienne Kembou; Pascal Milenge; Ibile Abessouguie; Armand S Nkwescheu; Zephirin Tsomo; Avelin F Aghokeng; Grace D Ngute; Peter M Ndumbe; Vittorio Colizzi; Jean B N Elat Journal: BMC Public Health Date: 2013-04-08 Impact factor: 3.295
Authors: James M Juma; Jenny K Tiberio; Mathias I Abuya; Bonita K Kilama; Geoffrey R Somi; Veryeh Sambu; Richard Banda; Boniphace S Jullu; Angela A Ramadhani Journal: BMC Infect Dis Date: 2014-04-11 Impact factor: 3.090